CellSeed Inc. (JP:7776)

:7776

7776

CellSeed Inc.

RESEARCH TOOLSreports

Want to see JP:7776 full AI Analyst Report?

CellSeed Inc. (7776) Price & Analysis

0 Followers

7776 Stock Chart & Stats

¥259.00

-¥7.00(-1.73%)

At close: Jan 08 4:00 PM EST

¥259.00

-¥7.00(-1.73%)

Day’s Range― - ―

52-Week Range¥225.00 - ¥597.00

Previous CloseN/A

Volume900.50K

Average Volume (3M)621.90K

Market Cap

¥9.09B

Enterprise Value¥7.80B

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta1.22

Next Earnings

Aug 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-7.24

Shares Outstanding39,160,420

10 Day Avg. Volume981,780

30 Day Avg. Volume621,903

Financial Highlights & Ratios

PEG Ratio-0.34

Price to Book (P/B)7.08

Price to Sales (P/S)107.39

P/FCF Ratio-8.85

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Niche Regenerative TechnologySpecialization in cell sheet engineering and regenerative cell therapies gives the company a durable technical moat in a high-barrier subsector. Clinical and manufacturing know-how, IP and specialized services support long-term partnership, licensing and commercial opportunities versus generalist biotech peers.

Healthy Gross MarginsSustained gross margins near mid-to-high single digits for biotech indicate solid unit economics and pricing power for products/services. These margins support the ability to fund R&D and scale manufacturing more efficiently if revenue recovers, improving long-term profitability potential.

Conservative Financial LeverageLow leverage reduces solvency risk during multi-year clinical or commercialization cycles, preserving flexibility to raise non-debt capital or invest in operations. Conservative debt levels lengthen runway versus highly leveraged peers and lower restructuring risk if revenues remain volatile.

Bears Say

Sharp Revenue DeteriorationA marked revenue decline erodes the base needed to absorb fixed R&D and manufacturing costs, signaling execution, demand or product-timing issues. Persistently lower top-line reduces operating leverage, lengthens time to breakeven, and weakens the fundamentals that underpin long-term growth.

Persistent Cash BurnContinuous negative operating and free cash flow forces reliance on external financing or dilution to fund operations. In a capital-intensive biotech model, ongoing cash burn without a clear path to self-funding increases refinancing risk and can constrain R&D, trials or commercialization investments.

Very Large Losses And Equity ErosionExtreme negative margins and declining equity reflect sustained structural unprofitability that erodes balance sheet strength. Continued losses raise dilution risk, weaken investor confidence and limit strategic options, making long-term viability dependent on substantial operational improvement or external funding.

CellSeed Inc. News

CellSeed Inc.’s Promising Phase III Study on Knee Osteoarthritis Treatment

CellSeed Inc. (($JP:7776)) announced an update on their ongoing clinical study. Study Overview: CellSeed Inc. is conducting a...

7M ago

7776

7776 FAQ

What was CellSeed Inc.’s price range in the past 12 months?

CellSeed Inc. lowest stock price was ¥225.00 and its highest was ¥597.00 in the past 12 months.

What is CellSeed Inc.’s market cap?

CellSeed Inc.’s market cap is ¥9.09B.

When is CellSeed Inc.’s upcoming earnings report date?

CellSeed Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 74 days.

How were CellSeed Inc.’s earnings last quarter?

CellSeed Inc. released its earnings results on May 13, 2026. The company reported -¥7.24 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.24.

Is CellSeed Inc. overvalued?

According to Wall Street analysts CellSeed Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does CellSeed Inc. pay dividends?

CellSeed Inc. does not currently pay dividends.

What is CellSeed Inc.’s EPS estimate?

CellSeed Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does CellSeed Inc. have?

CellSeed Inc. has 39,160,420 shares outstanding.

What happened to CellSeed Inc.’s price movement after its last earnings report?

CellSeed Inc. reported an EPS of -¥7.24 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.916%.

Which hedge fund is a major shareholder of CellSeed Inc.?

Currently, no hedge funds are holding shares in JP:7776

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

CellSeed Inc.

CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.